Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1993-02-18
2003-07-29
Housel, James (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S389400, C435S005000, C436S536000
Reexamination Certificate
active
06600023
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to antigens, means and methods for the diagnosis of lymphadenopathy and acquired immune deficiency syndrome.
The acquired immune deficiency syndrome (AIDS) has recently been recognized in several countries. The disease has been reported mainly in homosexual males with multiple partners, and epidemiological studies suggest horizontal transmission by sexual routes as well as by intravenous drug administration, and blood transfusion. The pronounced depression of cellular immunity that occurs in patients with AIDS and the quantitative modifications of subpopulations of their T lymphocytes suggest that T cells or a subset of T cells might be a preferential target for the putative infectious agent. Alternatively, these modifications may result from subsequent infections. The depressed cellular immunity may result in serious opportunistic infections in AIDS patients, many of whom develop Kaposi's sarcoma. However, a picture of persistent multiple lymphadenopathies has also been described in homosexual males and infants who may or may not develop AIDS. The histological aspect of such Lymph nodes is that of reactive hyperplasia. Such cases may correspond to an early or a milder form of the disease.
SUMMARY OF THE INVENTION
It has been found that one of the major etiological agents of AIDS and of lymphadenopathy syndrome (LAS), which is often considered as a prodromic sign of AIDS, should consist of a T-lymphotropic retrovirus which has been isolated from a lymph node of a homosexual patient with multiple lymphadenopathies. The virus appears to be distinct from the human T-cell leukemia virus (HTLV) family (R. C. Gallo and M. S. Reitz, “J. Natl. Cancer Inst.”, 69 (No. 6), 1209 (1982)). The last mentioned virus has been known as belonging to the so-called HTLV-1 subgroup.
The patient was a 33-year-old homosexual male who sought medical consultation in December 1982 for cervical lymphadenopathy and asthenia (patient 1). Examination showed axillary and inguinal lymphadenopathies. Neither fever nor recent loss of weight were noted. The patient had a history of several episodes of gonorrhea and had been treated for syphilis in September 1982. During interviews he indicated that he had had more than 50 sexual partners per year and had travelled to many countries, including North Africa, Greece, and India. His last trip to New York was in 1979.
Laboratory tests indicated positive serology (immunoglobulin G) for cytomegalovirus (CMV) and Epstein-Barr virus. Herpes simplex virus was detected in cells from his throat that were cultured on human and monkey cells. A biopsy of a cervical lymph node was performed. One sample served for histological examination, which, revealed follicular hyperplasia without change of the general structure of the lymph node. Immunohistological studies revealed, in paracortical areas, numerous T lymphocytes (OKT3
+
). Typing of the whole cellular suspension indicated that 62 percent of the cells were T lymphocytes (OKT3
+
), 44 percent were T-helper cells (OKT4
+
), and 16 percent were suppressor cells (OKT8
+
).
Cells of the same biopsed lymph node were put in culture medium with phytohemagglutinin (PHA), T-cell growth factor (TCGF), and antiserum to human a interferon (“The cells were grown in RPMI-1640 medium supplemented with antibiotics, 10
−5
M &bgr;-mercaptoethanol, 10 percent fetal calf serum, 0.1 percent sheep antibody to human &agr; interferon, neutralizing titer, 7 IU at 10
−5
dilution and 10 percent TCGF, free or PHA”). The reason for using the antiserum to &agr;-interferon was to neutralize endogenous interferon which is secreted by cells chronically infected by viruses, including retroviruses. In the mouse system, it had previously been shown that anti-serum to interferon could increase retrovirus production by a factor of 10 to 50 (F. Barre-Sinoussi et al., “Ann. Microbiol. (Institut Pasteur)” 1308, 349 (1979). After 3 days, the culture was continued in the same medium without PHA. Samples were regularly taken for reverse transcriptase assay and for examination in the electron microscope.
After 15 days of culture, a reverse transcriptase activity was detected in the culture supernatant by using the ionic conditions described for HTLV-I (B. J. Poiesz et al. “Proc. Natl. Acad. Sci. U.S.A.” 77, 7415 (1980)). Virus production continued for 15 days and decrease) thereafter, in parallel with the decline of lymphocyte proliferation. Peripheral blood lymphocytes cultured on the same way were consistently negative for reverse transcriptase activity, even after 6 weeks. Cytomegalovirus could be detected, upon prolonged co-cultivation with MRC5 cells, in the original biopsy tissue, but not in the cultured T lymphocytes at any time of the culture.
REFERENCES:
patent: 4323555 (1982-04-01), Theilen
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 4843011 (1989-06-01), Sarngadharan et al.
patent: 0116949 (1984-08-01), None
patent: 0745948 (1980-07-01), None
D. Marco Veronese et al., “Monoclonal Antibodies Specific for p24, The Major Core Protein of Human T-cell Leukemia Virus Type III,”Proc. Natl. Acad.Sci. USA, 82:5199-5202, Aug. 1985.*
Seaver, S.S.,Gen. Eng. News14(14):10,21, Aug. 1994.*
English language Abstract of Soviet Union Patent No. 0,745,948.
Barre-Sinoussi et al., Science, 220, pp. 868-871 (1983).
Gallo et al., J. Nat'l. Cancer Inst., 69(6), pp. 1209-1214 (1982).
Barre-Sinoussi et al., Ann. Microbiological. (Institut Pasteur), 130 B, pp. 349-362 (1979).
Poiesz et al., Proc. Nat'l. Acad. Sci., USA, 77(12), pp. 7415-7419 (1980).
Robert-Guroff et al., J. Exp. Med., 154, pp. 1957-1964 (1981).
Kalyanaraman et al., J. Virol., 38, pp. 906-915 (1981).
Popovic et al., Science, 219, pp. 856-859 (1983).
Montelaro et al., J. of Virology, 42(3), pp. 1029-1038 (1982).
Montagnier et al., “A New Human T-Lymphotropic Retrovirus . . . ”, reprinted from Human T-Cell Leukemia/Lymphoma Viruses, Cold Spring Harbor Laboratory, Gallo et al. eds., pp. 363-379 (1984).
Kalyanaraman et al, Science, 225, pp. 321-323 (1984).
Casey et al., J. of Virology, 55(2), pp. 417-423 (1985).
Saxinger et al., Laboratory Investigation, 49(3), pp. 371-377 (1983).
Renato Dulbecco, Oncogenic Viruses, Microbiology, Third Edition, pp. 1231-1261 (Harper & Row Publishers, 1980).
Chandra et al., Cold Spring Harbor Conference, Cell Proliferation, vol. 7 pp. 775-791 (1980).
Schetters et al., Infection and Immunity, 29(3), pp. 972-980 (1980).
Rho et al., Virology, 112, pp. 355-360 (1981).
Posner et al., J. of Exp. Med., 154, pp. 333-346 (1981).
Poiesz et al., Nature, 294, pp. 268-271 (1981).
Kalyanaraman et al., Nature, 294, pp. 271-273 (1981).
Miyoshi et al., Nature, 294, pp. 770-771 (1981).
Essex, Epidemiological Reviews, 4, pp. 189-203 (1982).
Oroszlan et al., Proc. Nat'l. Acad. Sci., USA, 79, pp. 1291-1294 (1982).
Morbidity and Motorality Weekly Report, 31(19), pp. 249-251 (1982).
Yamamoto et al., Science, 217, pp. 737-739 (1982).
Morbidity and Mortality Weekly Report, 31(37), pp. 507-514 (1982).
Blattner et al., Int. Journal of Cancer, 30, pp. 257-264 (1982).
Gallo et al., Blood, 60(3), pp. 545-557 (1982).
Essex, J. of the National Cancer Institute, 69(4), pp. 981-985 (1982).
Robert-Guroff et al., Virology, 122, pp. 297-305 (1982).
Haynes et al., J. of Exp. Med., 157, pp. 907-920 (1983).
Sarin et al., Proc. Natl. Acad. Sci., USA, 80, pp. 2370-2374 (1983).
Haynes et al., Proc. Natl. Acad. Sci., USA, 80, pp. 2054-2058 (1983).
Reitz et al., Virology, 126, pp. 688-692 (1983).
Morbidity and Mortality Weekly Report, 32(18), pp. 233-234 (1983).
Marx, Science, 220, pp. 806-809 (1983).
Trainin et al., Science, 220, pp. 858-859 (1983).
Essex et al., Science, 220, pp. 859-862 (1983).
Gallo et al., Science, 220, pp. 865-867 (1983).
Journal of the American Medical Association, 249(21), pp. 2878-2879 (1983).
De Jong et al., The Lancet, pp. 1293-1296 (1983).
Morbidity and Mortality Weekly Report, 32(24), pp. 309-311 (1983).
Seiki et al., Proc. Natl. Acad. Sci., USA, 8
Axler-Blin Claudine
Barre-Sinoussi Francoise
Brun-Vezinet Francoise
Chamaret Solange
Chermann Jean-Claude
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Housel James
Institut Pasteur
LandOfFree
Antibody directed against HIV-1 P25 antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody directed against HIV-1 P25 antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody directed against HIV-1 P25 antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3078892